APGE
Apogee Therapeutics, Inc.
Latest Form 4:Sale$738KbyDambkowski Carl (Chief Medical Officer) · filed Aug 8, 2026
Apogee Therapeutics, Inc. (APGE) has 41 SEC Form 4 filings (101 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Aug 11, 2026.
The most active filer is Chief Medical Officer Dambkowski Carl with 13 filings. Insiders have net sold $28.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Michael Thomas Henderson
- Employees:261
- HQ:Waltham, MA, US
- IPO:2023-07-14
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$174.3M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$10.2B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 5,500 | $738K | Aug 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $2.7M | Jul 11 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $730K | Jul 2 | SEC ↗ | |
| Chief Medical Officer | Sale | 26,400 | $3.5M | Jun 25 | SEC ↗ | |
| Chief Executive Officer | Sale | 80,000 | $10.6M | Jun 25 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.7M | Jun 12 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $433K | Jun 6 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.6M | May 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $463K | May 8 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $164K | May 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $180K | Apr 17 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.7M | Apr 10 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $467K | Apr 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $170K | Apr 3 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $170K | Mar 27 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.5M | Mar 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $391K | Mar 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $140K | Mar 4 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.3M | Feb 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,500 | $362K | Feb 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $132K | Feb 4 | SEC ↗ | |
| Director | Sale | 1,750,000 | $133.5M | Jan 22 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.6M | Jan 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 18,700 | $1.5M | Jan 9 | SEC ↗ | |
| Chief Financial Officer | Sale | 6,000 | $449K | Jan 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $160K | Jan 6 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,500 | $120K | Dec 23 | SEC ↗ | |
| Chief Executive Officer | Sale | 20,000 | $1.5M | Dec 12 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.0M | Dec 5 | SEC ↗ | |
| Chief Medical Officer | Sale | 10,900 | $818K | Dec 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,500 | $113K | Dec 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 1,500 | $105K | Nov 28 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,000 | $130K | Nov 14 | SEC ↗ | |
HENDERSON MICHAEL THOMASFirst filing | Chief Executive Officer | Sale | 20,000 | $1.3M | Nov 13 | SEC ↗ |
Henderson JaneFirst filing | Chief Financial Officer | Sale | 1,000 | $60K | Nov 13 | SEC ↗ |
| Chief Medical Officer | Sale | 10,785 | $594K | Nov 7 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,110 | $203K | Oct 3 | SEC ↗ | |
Dambkowski CarlFirst filing | Chief Medical Officer | Sale | 2,725 | $103K | Sep 5 | SEC ↗ |
Related companies
Apogee Therapeutics, Inc. is in the Healthcare sector.